Why did Medline lower its full-year adjusted EBITDA guidance even as it raised its organic sales growth outlook during its Q2 2026 earnings call?
Medline's sales are booming, but its costs are biting with equal force. During its August 5, 2026 results update and conference call 1 3 , the company raised its full year 2026 organic sales growth outlook while cutting its full year adjusted EBITDA outlook. The guidance moved in opposite directions...
2000